Search

Your search keyword '"Angelico, M"' showing total 76 results

Search Constraints

Start Over You searched for: Author "Angelico, M" Remove constraint Author: "Angelico, M" Topic humans Remove constraint Topic: humans
76 results on '"Angelico, M"'

Search Results

1. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

2. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

3. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

4. Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation

5. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

6. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

7. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

8. A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a 'Blended Principle Model'

9. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference

10. Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

11. [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]

12. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients

13. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

14. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

15. Short-Term, Low-Dose Use of Tolvaptan as a Bridge Therapy to Expedite Liver Transplant for Severe Hyponatremic, Cirrhotic Patients With High Model for End-Stage Liver Disease Scores

16. Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study

17. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients

18. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

19. Practice of adult liver transplantation in Italy. Recommendations of the Italian Association for the Study of the Liver (A.I.S.F.)

20. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

21. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C

22. Patterns of chronic hepatitis B in Central Italy: a cross-sectional study

23. Treatment of chronic hepatitis B: recommendations from an Italian workshop

24. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C

25. Liver transplantation in the presence of portal vein thrombosis: report from a single center

26. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation

27. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

28. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C

29. One-Year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation

31. Uptake on Helicobacter pylori research. Pathogenesis and host response

32. Effect of taurohyodeoxycholic acid on biliary lipid secretion in man: preliminary report

33. Qualitative patterns of biliary bile acids affect cyclosporine intestinal absorption in liver transplant recipients

34. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up

35. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients

36. Plasma lipid lipoproteins and biliary lipid composition in female gallstone patients

37. The epidemiology of gallstone disease in Rome, Italy. Part II. Factors associated with the disease. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO)

39. [Serum bile acids in congestive heart failure]

41. Different levels of variability in subtypes 1b and 4a of hepatitis C viruses

42. The effects of maintenance doses of FK506 versus cyclosporin a on glucose and lipid metabolism after orthotopic liver transplantation

43. Sequential changes in serum and biliary bile acids after liver transplantation

44. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

45. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

46. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection

47. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

48. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

49. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

50. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

Catalog

Books, media, physical & digital resources